Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I clinical trial of ENV-294

Next Previous
X
Search
Trial Profile

A Phase I clinical trial of ENV-294

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ENV 294 (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions

    • Most Recent Events

    • 20 Nov 2024 New trial record
    • 13 Nov 2024 According to Enveda media release, company announced, U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for its first asset targeting atopic dermatitis and other inflammatory conditions. The company initiated phase I clinical trial and first patient dosed at the end of October.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top